April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Visual Field Progression Outcomes in Glaucoma Subtypes
Author Affiliations & Notes
  • Francisco A. Folgar
    Ophthalmology, New York University Medical Center, New York, New York
  • Gustavo V. De Moraes
    Ophthalmology, New York University Medical Center, New York, New York
  • Craig A. Liebmann
    Ophthalmology, New York University Medical Center, New York, New York
  • Robert Ritch
    Ophthalmology, New York Eye & Ear Infirmary, New York, New York
  • Jeffrey M. Liebmann
    Ophthalmology, New York University Medical Center, New York, New York
  • Footnotes
    Commercial Relationships  Francisco A. Folgar, None; Gustavo V. De Moraes, None; Craig A. Liebmann, None; Robert Ritch, None; Jeffrey M. Liebmann, None
  • Footnotes
    Support  Supported by the James Cox Chambers Research Fund of the New York Glaucoma Research Institute, New York, NY
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5051. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Francisco A. Folgar, Gustavo V. De Moraes, Craig A. Liebmann, Robert Ritch, Jeffrey M. Liebmann; Visual Field Progression Outcomes in Glaucoma Subtypes. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5051.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

To determine whether glaucoma subtype is an independent risk factor for visual field (VF) progression.


We reviewed the charts of glaucoma suspects and glaucoma patients seen in a referral practice between 1999 and 2009. Automated pointwise linear regression analysis determined rates of VF change. A progression endpoint was determined when 2 or more adjacent test locations in the same hemifield showed a threshold sensitivity decline at a rate of ≥1.0 dB/yr with p<0.01.


We included 841 eyes (841 patients; mean age, 64.1±12.6 yrs; mean number of VF tests, 10.8±2.8; mean follow-up, 6.4±1.7 yrs). The glaucoma group consisted of angle-closure glaucoma (ACG, 76 eyes), juvenile primary open-angle glaucoma (JPOAG, 37 eyes), normal-tension glaucoma (NTG, 81 eyes), pigmentary glaucoma (PG, 34 eyes), primary open-angle glaucoma (POAG, 275 eyes), and exfoliative glaucoma (XFG, 84 eyes). NTG eyes were more likely to present with beta-zone parapapillary atrophy and disc hemorrhage (p<0.01). XFG eyes had the fastest rates of global VF change (-0.65 dB/yr), as well as the highest mean, fluctuation, and peak IOP during follow-up (16.5, 3.0, and 22.0 mmHg, respectively) and reached a progression endpoint more frequently (40%). After adjusting for all covariates, including the glaucoma phenotype, there was no difference among groups regarding global rates of VF change and the risk of reaching a progression endpoint.


Despite different clinical features, epidemiology and genetics, glaucoma phenotype is not an independent risk factor for VF progression. Rather, variations in well-known, reported risk factors remain important disease parameters that affect progression.  

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • visual fields • intraocular pressure 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.